The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein.

MUC1 proteins, some of which contain a mucin-like domain and others lacking this region, can be generated from the human breast cancer-associated MUC1 gene by alternative splicing. The MUC1/Y isoform is devoid of the mucin domain and is a cell membrane protein that undergoes transphosphorylation on both serine and tyrosine residues. We have identified cognate binding proteins that specifically interact with the extracellular domain of MUC1/Y. Coimmunoprecipitation analyses clearly revealed the presence of complexes composed of MUC1/Y and its cognate binding proteins in primary breast tumor tissue. MUC1/Y-expressing mammary tumor cells can be specifically targeted, in vivo, with the labeled cognate binding protein. The k(D) of MUC1/Y for its binding proteins was estimated as 1.2 nM. The MUC1/Y binding proteins are also derived from the MUC1 gene and represent the secreted mucin-like polymorphic MUC1 proteins MUC1/SEC and MUC1/REP, which contain a tandem repeat array. Whereas nonposttranslationally modified MUC1/Y bound efficiently to MUC1/SEC, the latter mucin-like protein had to be posttranslationally modified in a cell-type specific manner to bind MUC1/Y. The interaction of MUC1/Y with MUC1/SEC has important biological functional correlates: (a) it induces MUC1/Y phosphorylation; and (b) it has a pronounced effect on cell morphology. These findings suggest that MUC1/Y and MUC1/SEC form an active receptor/ cognate binding protein complex that can elicit cellular responses. The proteins comprising this complex are, thus, generated by alternative splicing from one and the same gene, namely the MUC1 gene.

[1]  O. Elroy-Stein,et al.  Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue. , 1994, European journal of biochemistry.

[2]  M. Reddish,et al.  Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. , 1997, Journal of immunotherapy.

[3]  J. Aplin,et al.  MUC1 as a Cell Surface and Secretory Component of Endometrial Epithelium: Reduced Levels in Recurrent Miscarriage , 1996, American journal of reproductive immunology.

[4]  S. J. Ruff,et al.  Peroxovanadate Induces Tyrosine Phosphorylation of Multiple Signaling Proteins in Mouse Liver and Kidney* , 1997, The Journal of Biological Chemistry.

[5]  P. Linsley,et al.  Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients. , 1988, Cancer research.

[6]  M. Ligtenberg,et al.  Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. , 1990, The Journal of biological chemistry.

[7]  D. Kufe,et al.  Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. , 1995, Cancer research.

[8]  O. Elroy-Stein,et al.  Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins Cytokine receptor‐like molecules , 1994, FEBS letters.

[9]  Sandra J. Gendler,et al.  Delayed Mammary Tumor Progression in Muc-1 Null Mice (*) , 1995, The Journal of Biological Chemistry.

[10]  Y. Kan,et al.  Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. , 1994, Science.

[11]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[12]  M. Ligtenberg,et al.  Cell-associated episialin is a complex containing two proteins derived from a common precursor. , 1992, The Journal of biological chemistry.

[13]  M. Price,et al.  Targeting of bladder cancer with monoclonal antibody NCRC48--a possible approach for intravesical therapy. , 1995, British journal of urology.

[14]  D. Schmitt,et al.  Hyperphosphorylation of β-Catenin on Serine-Threonine Residues and Loss of Cell–Cell Contacts Induced by Calyculin A and Okadaic Acid in Human Epidermal Cells☆ , 1997 .

[15]  H. Aberle,et al.  Cadherin‐catenin complex: Protein interactions and their implications for cadherin function , 1996, Journal of cellular biochemistry.

[16]  N. Smorodinsky,et al.  Detection of a secreted MUC1/SEC protein by MUC1 isoform specific monoclonal antibodies. , 1996, Biochemical and biophysical research communications.

[17]  D. Kufe,et al.  Interaction of the DF3/MUC1 Breast Carcinoma-associated Antigen and β-Catenin in Cell Adhesion* , 1997, The Journal of Biological Chemistry.

[18]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[19]  J. Taylor‐Papadimitriou,et al.  The product of the human MUC1 gene when secreted by mouse cells transfected with the full-length cDNA lacks the cytoplasmic tail. , 1992, Biochemical and biophysical research communications.

[20]  I. Mckenzie,et al.  Second generation anti-MUC1 peptide monoclonal antibodies. , 1992, Cancer research.

[21]  J. Taylor‐Papadimitriou,et al.  Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. , 1987, Cancer research.

[22]  T. Mehlman,et al.  Detection and characterization of heparin-binding proteins with a gel overlay procedure. , 1990, Analytical biochemistry.

[23]  M. Ligtenberg,et al.  Cell membrane-associated mucins and their adhesion-modulating property. , 1992, Trends in biochemical sciences.

[24]  K. Lloyd,et al.  Comparison of MUC‐1 mucin expression in epithelial and non‐epithelial cancer cell lines and demonstration of a new short variant form (MUC‐1/Z) , 1997, International journal of cancer.

[25]  J. Bazan,et al.  Structural design and molecular evolution of a cytokine receptor superfamily. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Zipursky,et al.  Interaction of bride of sevenless membrane-bound ligand and the sevenless tyrosine-kinase receptor , 1991, Nature.

[27]  I. Tsarfaty,et al.  Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  N. Peat,et al.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.

[29]  R. Lathe,et al.  Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms. , 1990, European journal of biochemistry.

[30]  R. Ceriani,et al.  Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE‐3 in breast‐cancer prognosis , 1992, International journal of cancer.

[31]  M. King,et al.  Inherited breast and ovarian cancer. , 1995, Human molecular genetics.

[32]  Walsh,et al.  Prognostic significance of MUC1 epithelial mucin expression in breast cancer. , 1995, Human pathology.

[33]  R. Lathe,et al.  Human epithelial tumor antigen cDNA sequences , 1990 .

[34]  D. Kufe,et al.  Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Brian Seed,et al.  PSGL-1 recognition of P-selectin is controlled by a tyrosine sulfation consensus at the PSGL-1 amino terminus , 1995, Cell.

[36]  E. Cooper,et al.  Use of mucin like cancer associated antigen (MCA) in the management of breast cancer. , 1991, British Journal of Cancer.

[37]  K. Comess,et al.  A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding , 1995, Cell.

[38]  J. Louis,et al.  GDNF–Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR-α, a Novel Receptor for GDNF , 1996, Cell.

[39]  N. Smorodinsky,et al.  Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor‐potentiating function , 1997, International journal of cancer.

[40]  M. Ligtenberg,et al.  Suppression of cellular aggregation by high levels of episialin. , 1992, Cancer research.

[41]  D. Schmitt,et al.  Hyperphosphorylation of beta-catenin on serine-threonine residues and loss of cell-cell contacts induced by calyculin A and okadaic acid in human epidermal cells. , 1997, Experimental cell research.